Thermal ablation is heating tumors so hot that the tumor cells die. It has been studied in many forms, including microwave, laser, high-intensity focused ultrasound, and cryotherapy (freezing below -20 C). Radiofrequency thermal ablation or radiofrequency ablation (RFA) has emerged as the most commonly used technology for thermal ablation in the bone, liver, kidney, lung, heart, breast, lymph nodes, nerve ganglia, and soft tissue.
DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced an upcoming poster presentation at the World Congress of Interventional Oncology (WCIO), June 14-18 in Chicago.
Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.
Studies of technological innovations being presented for the first time at Digestive Disease Week- (DDW) showed increased accuracy coupled with decreased cost, time or invasiveness of gastrointestinal procedures. Use of a new high-definition colonoscope, for example, improved physician confidence in diagnosing small polyps, potentially reducing the amount of polyps sent for pathology analysis and the associated costs.
Patients with the heart rhythm disorder atrial fibrillation (AFib) who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving antiarrhythmic drugs, the standard first-line treatment.
Radiofrequency ablation of the lumpectomy site during breast cancer surgery can provide an effective alternative to post-operative external radiation therapy (XRT) and reduce repeat surgeries to achieve clear tumor margins, according to one of the first published long-term studies to examine this new treatment protocol.
Thomas Jefferson University Hospital announces the opening of its new Jefferson Barrett's Esophagus Treatment Center, one of only a few dedicated Barrett's centers in the country and the first multidisciplinary center solely dedicated to treating Barrett's esophagus disease in Philadelphia.
Boston Scientific Corporation announces the U.S. market launch of its Z Flex-270 Steerable Sheath. The device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.
The University of Alabama at Birmingham has a number of presentations and experts available to comment on news being presented at the annual American College of Cardiology Scientific Sessions that begin Saturday, March 23, 2012, in Chicago.
Boston Scientific Corporation today announced Health Canada approval of the Blazer Open-Irrigated Catheter, the Company's latest radiofrequency ablation (RFA) catheter designed to treat a variety of arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia and other supraventricular tachycardias.
Heartburn. Acid reflux, GERD. They're different terms for the same type of condition - stomach acid used for digestion travels back up the esophagus, the "food pipe" that connects your throat to your stomach.
'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment
For patients undergoing a minimally invasive treatment for liver cancer, the risk of recurrent cancer appears lower with general anesthesia compared to regional (epidural) anesthesia, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
Researchers at Columbia University Medical Center (CUMC) have identified the critical early cellular and molecular events that give rise to a type of esophageal cancer called esophageal adenocarcinoma, the fastest-rising solid tumor in the United States.
Covidien, a leading global provider of healthcare products, today announced that Radiology, the monthly journal of the Radiological Society of North America, has published a new research study led by Prof. Thomas J. Vogl, MD, entitled, "Microwave Ablation Therapy: Clinical Utility in Treatment of Pulmonary Metastases."
A research group at the Perelman School of Medicine of the University of Pennsylvania, led by John Lynch, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology, has received a National Cancer Institute (NCI) grant to establish a Barrett's esophagus translational research network (BETRNet) with Columbia University and the Mayo Clinic.
Medtronic, Inc. today announced results from its Tailored Treatment of Permanent Atrial Fibrillation clinical trial, the first randomized study comparing ablation therapy with the Medtronic Phased RF Ablation System ablation system to traditional medical management in 210 patients with persistent or long-standing persistent atrial fibrillation.
Gynesonics, Inc., a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, today announced the start of, and initial treatments in, the FAST-EU Trial, a multicenter clinical study to demonstrate the effectiveness of the VizAblate® procedure for the treatment of uterine fibroids associated with heavy menstrual bleeding.
InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that its investigational ExAblate(R) Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.
Many patients are responding to a new, minimally invasive way of treating irregular heartbeats by freezing out the bad cells. Atrial fibrillation (A-Fib) is one such heart rhythm disorder, and it's the most common arrhythmia affecting Americans.
The journal Radiology will publish in its September issue an article written by Damian E. Dupuy, M.D., director of tumor ablation at Rhode Island Hospital, supporting the use of ablation procedures for the treatment of lung cancer.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.